Back to results

print
Stem cells treatment for patients with heart diseases

Source agency:
AETSA
Date of Submission:
02/12/2009
Date of Printing:
05/02/2012
Disclaimer:
This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.

Technology, Company & Licensing

Technology name:
Stem cells
Technology - description:
Cellular cardiomyoplasty with stem cells is a possible option to reverse the adverse hemodynamic and neurohormonal imbalance after myocardial infarction. It is an outside intervention to support the reparative process in the heart through transplantation of stem/progenitor cells or cardiac cells, or mobilizing peripheral blood or bone marrow-derived stem cells into the site of cardiac injury.
Stem cells are capable of self-
renewal and differentiation to specialized progeny.
Company or developer:
 
Reason for database entry:
Innovative tretament with major health expect health benefit
Technology - stage in early warning process:
Assessment complete
Technology - stage of development:
Experimental - pilot or phase II
Licensing, reimbursement and other approval:
 
Technology - type(s):
Procedure
Technology - use(s):
Therapeutic

Patient Indication & Setting

Patient indications:
Myocardial infarction is the leading cause of congestive heart failure and death in the industrialized world
Disease description and associated mortality and morbidity:
Prognosis from heart failure is poor. Data from the London Heart Failure Study showed that around 40% of people die within one year of an initial diagnosis of heart failure
Number of Patients:
 
Technology - specialities(s):
Cardiovascular disease & vascular surgery
Technology - setting(s):
Specialist hospital
Setting - further information:
 

Impact

Alternative and/or complementary technology:
Other
Current Technology:
 
Health Impact:
 
Diffusion:
 
Cost, infrastructure and economic consequences:
New structures and staff with adequate training in molecular biology
Ethical, social, legal, political and cultural impact:
 

Evidence & Policy

Clinical evidence and safety:
After eliminating the studies that did not satisfied the inclusion criteria, 9 studies were selected. Seven of them were randomized clinical trial
Economic evaluation:
 
Ongoing research:
 
Ongoing or planned HTA:
 
Web link:
www.juntadeandalucia.es/salud/aetsa
References and sources:
5. Schächinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol. 2004;44:1690-9.[Medline]
13. Chen S, Liu Z, Tian N, Zhang J, Yei F, Duan B, et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol. 2006;18:552-6.[Medline]
14. Engelmann MG, Theiss HD, Hennig-Theiss C, Huber A, Wintersperger BJ, Werle-Ruedinger AE, et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol. 2006;48:1712-21.[Medline]
15. Hristov M, Heussen N, Schober A, Weber C. Intracoronary infusion of autologous bone marrow cells and left ventricular function after acute myocardial infarction: a meta-analysis. J Cell Mol Med. 2006;10:727-33.[Medline]
16. Ince H, Petzsch M, Kleine HD, Eckard H, Rehders T, Burska D, et al. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation. 2005;112:I73-I80.[Medline]
17. Kang HJ, Kim HS, Koo BK, Kim YJ, Lee D, Sohn DW, et al. Intracoronary infusion of the mobilized peripheral blood stem cell by G-CSF is better than mobilization alone by G-CSF for improvement of cardiac function and remodeling: 2-year follow-up results of the Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and Intra-Coronary Stem Cell Infusion (MAGIC Cell) 1 trial. Am Heart J. 2007;153:237-8.[Medline]
18. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Forfang K. Autologous stem cell transplantation in acute myocardial infarction: the ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J. 2005;39:150-8.[Medline]
19. Schaefer A, Meyer GP, Fuchs M, Klein G, Kaplan M, Wollert KC, et al. Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: results from the BOOST trial. Eur Heart J. 2006;27:929-35.[Medline]
20. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167:989-97.[Medline]
Notes: